This week on the pod we look at results from a COVID-19 prevention trial of hydroxychloroquine; A vaccine arrival date prediction by Dr Fauci; A FDA notification regarding vial caps; A look into prescription patterns during COVID-19; And an antibody treatment trial begins.
The FDA is notifying healthcare professionals regarding the temporary absence of the “paralyzing agent” warning statement on vial caps of vecuronium bromide for injection
Excess of 80 ectopic pregnancies per 10,000 pregnancies found in women with benzodiazepine prescription.
Patients on hemodialysis who use opioids concurrently with a short-acting benzodiazepine are especially at risk for early death, a study found.
Galcanezumab was found to significantly improve work productivity and reduce interictal burden in patients with treatment-resistant migraine, according to results from the phase 3 CONQUER study.
Biota Biosciences announced the voluntary recall of CBD Complex, Curcumin Complex, and Cannabidiol + Curcumin Injectables due to the products being marketed without the approval of the FDA.
“In context of the recent rise in supply and demand of compounded preparations, lack of evidence regarding systemic absorption of ingredients used in compounded topical pain creams gives rise to a substantial public health concern,” the authors concluded.
This week we cover the the risk of antihypertensive med use during the pandemic; The Emergency Use Authorization for remdesivir in hospitalized patients with suspected or confirmed COVID-19; The addition of a Boxed Warning to Montelukast; A new Farxiga indication; And a novel treatment for acute migraines.
The FDA has approved Elyxyb (Dr. Reddy’s Laboratories), an oral solution formulation of celecoxib, for the acute treatment of migraine with or without aura in adults.
Ajovy (fremanezumab-vfrm; Teva) is now available in an autoinjector device for the preventive treatment of migraine in adults.
